These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Snoeck R, Andrei G, Gérard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N, De Clercq E. Clin Infect Dis; 1994 Apr 28; 18(4):570-8. PubMed ID: 8038312 [Abstract] [Full Text] [Related]
10. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. Czartoski T, Liu C, Koelle DM, Schmechel S, Kalus A, Wald A. J Clin Microbiol; 2006 Apr 28; 44(4):1584-6. PubMed ID: 16597901 [Abstract] [Full Text] [Related]
13. Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents. Cotarelo M, Catalán P, Sánchez-Carrillo C, Menasalvas A, Cercenado E, Tenorio A, Bouza E. J Antimicrob Chemother; 1999 Nov 28; 44(5):705-8. PubMed ID: 10552991 [Abstract] [Full Text] [Related]